Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) emphasized the global trends driving demand for advanced breast cancer imaging technologies and the advantages of its IzoView Breast CT Imaging System. With over 2.3 million new cases of breast cancer diagnosed worldwide annually and U.S. incidence projected to exceed 315,000 in 2025, healthcare systems face growing pressure to improve screening outcomes. Market forecasts show global breast imaging revenues rising from $5.4 billion in 2024 to $8.69 billion by 2030. IzoView addresses clinical and patient needs with non-compressive 3D imaging, offering a more comfortable, accurate, and scalable alternative to conventional modalities—especially for the 50% of women with dense breast tissue.
To view the full press release, visit https://ibn.fm/0Zq49
About Izotropic
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca
NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
